KF 20444
Latest Information Update: 10 Nov 2006
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Class Anti-inflammatories; Antirheumatics; Biphenyl compounds; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 26 Jul 2001 No-Development-Reported for Rheumatoid arthritis in Japan (Unknown route)
- 26 Jul 2001 No-Development-Reported for Transplant rejection in Japan (Unknown route)
- 19 Jan 1999 Preclinical development for Transplant rejection in Japan (Unknown route)